Endometrium neoplasm
diseaseOn this page
Also known as endometrial neoplasmendometrial tumorendometrial tumourendometrium neoplasm (disease)endometrium tumorendometrium tumourneoplasm of endometriumneoplasm of the endometriumtumor of endometriumtumor of the endometriumtumour of endometriumtumour of the endometrium
Summary
Endometrium neoplasm (MONDO:0021251) is a cancer and 116 clinical trials. Top therapeutic interventions include paclitaxel, lenvatinib, and pembrolizumab. A subtype of endometrial disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 116
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endometrium neoplasm |
| Mondo ID | MONDO:0021251 |
| MeSH | D016889 |
| NCIT | C3012 |
| SNOMED CT | 123844007 |
| UMLS | C0014170 |
| MedGen | 8619 |
| Anatomy (UBERON) | UBERON:0001295 |
| Is cancer (heuristic) | yes |
Also known as: endometrial neoplasm · endometrial tumor · endometrial tumour · endometrium neoplasm (disease) · endometrium tumor · endometrium tumour · neoplasm of endometrium · neoplasm of the endometrium · tumor of endometrium · tumor of the endometrium · tumour of endometrium · tumour of the endometrium
Disease family
This is a subtype of endometrial disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › endometrial disorder › endometrium neoplasm
Related subtypes (6): endometritis, tamoxifen-related endometrial lesion, endometriosis, atypical endometrial hyperplasia, endometrial polyp, adenomyosis
Subtypes (4): endometrial stromal tumor, endometrial cancer, benign neoplasm of endometrium, fallopian tube endometrioid tumor
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 24 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Dostarlimab | Approved (phase 4) |
| Pembrolizumab | Approved (phase 4) |
| Albumin Human | Phase 3 (in late-stage trials) |
| Atezolizumab | Phase 3 (in late-stage trials) |
| Benmelstobart | Phase 3 (in late-stage trials) |
| Carboplatin | Phase 3 (in late-stage trials) |
| Cisplatin | Phase 3 (in late-stage trials) |
| Doxorubicin | Phase 3 (in late-stage trials) |
| Durvalumab | Phase 3 (in late-stage trials) |
| Estrogens, Conjugated | Phase 3 (in late-stage trials) |
| Fibrin | Phase 3 (in late-stage trials) |
| Filgrastim | Phase 3 (in late-stage trials) |
| Ifosfamide | Phase 3 (in late-stage trials) |
| Ixabepilone | Phase 3 (in late-stage trials) |
| Lenvatinib | Phase 3 (in late-stage trials) |
| Letrozole | Phase 3 (in late-stage trials) |
| Medroxyprogesterone Acetate | Phase 3 (in late-stage trials) |
| Megestrol Acetate | Phase 3 (in late-stage trials) |
| Metformin | Phase 3 (in late-stage trials) |
| Olaparib | Phase 3 (in late-stage trials) |
| Paclitaxel | Phase 3 (in late-stage trials) |
| Sacituzumab Govitecan | Phase 3 (in late-stage trials) |
| Sacituzumab Tirumotecan | Phase 3 (in late-stage trials) |
| Selinexor | Phase 3 (in late-stage trials) |
| TECHNETIUM TC 99M TILMANOCEPT | Phase 3 (in late-stage trials) |
| Zoptarelin Doxorubicin | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Abemaciclib, Alpelisib, Alvocidib, Amifostine, Aspirin, Avelumab, Axitinib, Bevacizumab, Buparlisib, Camrelizumab, Catequentinib, Celecoxib, Cetuximab, Cimetidine, Cridanimod, Crizotinib, Curcumin, Dactolisib, Danazol, Dexamethasone, Diphenhydramine, Dordaviprone, Dovitinib, Envafolimab, Epacadostat, Ergocalciferol, Ethinyl Estradiol, Everolimus, Exemestane, Fulvestrant, Gedatolisib, Gemcitabine, Giredestrant, Irofulven, Lansoprazole, Lifileucel, Mifepristone, Mirvetuximab Soravtansine, Navtemadlin, Nintedanib, Niraparib, Norgestrel, Oxaliplatin, Palbociclib, Pemigatinib, Progesterone, Raloxifene, Retifanlimab, Ridaforolimus, Rubitecan, Rucaparib, Sintilimab, Sitravatinib, Talazoparib, Tamoxifen, Temsirolimus, Tilmanocept, Topotecan, Trastuzumab, Trastuzumab Duocarmazine.
Clinical trials & evidence
Clinical trials
Clinical trials: 116.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 66 |
| PHASE2 | 20 |
| PHASE1 | 13 |
| PHASE3 | 9 |
| PHASE1/PHASE2 | 5 |
| PHASE2/PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01820858 | PHASE3 | ACTIVE_NOT_RECRUITING | The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma |
| NCT04269200 | PHASE3 | ACTIVE_NOT_RECRUITING | Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer |
| NCT04634877 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) |
| NCT05173987 | PHASE3 | ACTIVE_NOT_RECRUITING | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) |
| NCT05316935 | PHASE2/PHASE3 | RECRUITING | GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients |
| NCT05770102 | PHASE2/PHASE3 | RECRUITING | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition |
| NCT06379113 | PHASE2/PHASE3 | RECRUITING | GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients |
| NCT07578649 | PHASE3 | NOT_YET_RECRUITING | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer |
| NCT02564276 | PHASE3 | COMPLETED | Indocyanine Green Versus Blue Dye for Detection of Sentinel Lymph Node In Endometrial Cancer |
| NCT03517449 | PHASE3 | COMPLETED | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) |
| NCT03884101 | PHASE3 | COMPLETED | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) |
| NCT04865289 | PHASE3 | COMPLETED | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study |
| NCT04008797 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor |
| NCT04956640 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) |
| NCT05682950 | PHASE2 | ACTIVE_NOT_RECRUITING | Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer |
| NCT05795244 | PHASE2 | RECRUITING | Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) |
| NCT05869123 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer |
| NCT06003231 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 |
| NCT06023862 | PHASE2 | RECRUITING | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) |
| NCT06502743 | PHASE2 | RECRUITING | First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial Cancer |
| NCT06532539 | PHASE2 | RECRUITING | Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma |
| NCT00050440 | PHASE2 | COMPLETED | Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma |
| NCT00178802 | PHASE2 | UNKNOWN | Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers |
| NCT00377520 | PHASE2 | COMPLETED | A Trial for Patients With Advanced/Recurrent Endometrial Cancer |
| NCT01013324 | PHASE2 | COMPLETED | Study of XL147 (SAR245408) in Advanced or Recurrent Endometrial Carcinoma |
| NCT01420081 | PHASE2 | TERMINATED | A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer |
| NCT01460979 | PHASE2 | COMPLETED | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma |
| NCT01717391 | PHASE2 | COMPLETED | [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers |
| NCT02725268 | PHASE2 | COMPLETED | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer |
| NCT03005015 | PHASE2 | WITHDRAWN | Lenvatinib in Second Line Endometrial Carcinoma |
| NCT03276013 | PHASE2 | COMPLETED | Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer |
| NCT03570437 | PHASE2 | UNKNOWN | Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel? |
| NCT03951415 | PHASE2 | UNKNOWN | Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer |
| NCT04570839 | PHASE1/PHASE2 | COMPLETED | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. |
| NCT04870177 | PHASE2 | COMPLETED | Study of AK112 in the Treatment of Advanced Gynecological Tumors |
| NCT05001282 | PHASE1/PHASE2 | TERMINATED | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) |
| NCT05007106 | PHASE2 | COMPLETED | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) |
| NCT06400472 | PHASE1 | RECRUITING | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors |
| NCT06586957 | PHASE1 | RECRUITING | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors |
| NCT06714617 | PHASE1 | ACTIVE_NOT_RECRUITING | Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PACLITAXEL | 4 | 15 |
| LENVATINIB | 4 | 4 |
| PEMBROLIZUMAB | 4 | 2 |
| DOSTARLIMAB | 4 | 1 |
| DURVALUMAB | 4 | 1 |
| GONADORELIN ACETATE | 4 | 1 |
| INULIN | 4 | 1 |
| OLAPARIB | 4 | 1 |
| PONATINIB | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| TRABECTEDIN | 4 | 1 |
| ZOLPIDEM | 4 | 1 |
| CEDIRANIB | 3 | 1 |
| DISITAMAB VEDOTIN | 3 | 1 |
| GEDATOLISIB | 3 | 1 |
| IVONESCIMAB | 3 | 1 |
| OLOMORASIB | 3 | 1 |
| FELMETATUG VEDOTIN | 2 | 1 |
| NESUPARIB | 2 | 1 |
| PILARALISIB | 2 | 1 |
| SAPANISERTIB | 2 | 1 |
| SERABELISIB | 2 | 1 |
| E-7386 | 1 | 1 |
| PASIFOLATE EXATECAN | 1 | 1 |
| CHEMBL2370644 | 0 | 1 |
| CHEMBL3962632 | 0 | 1 |
| CHEMBL3991933 | 0 | 1 |
| CHEMBL1171086 | 0 | 1 |
| CHEMBL4519289 | 0 | 1 |